Patents by Inventor Eli A. Stahl

Eli A. Stahl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Materials and methods of treating MHC-I-opathy risk haplotypes
    Patent number: 12370257
    Abstract: The present disclosure provides methods of treating subjects having an immune disorder by administering to the subject a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor in combination with an HLA-A29 or HLA-B27 inhibitory nucleic acid molecule.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: July 29, 2025
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Jack A. Kosmicki, Manuel Allen Revez Ferreira, Carmelo Romano
  • Treatment Of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Inhibitors
    Publication number: 20250115918
    Abstract: The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.
    Type: Application
    Filed: October 24, 2024
    Publication date: April 10, 2025
    Inventors: Sahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Carmelo Romano, Santiago Mendez Huergo, Jonathan Weyne, Tave Van Zyl
  • Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitors
    Patent number: 12157891
    Abstract: The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: December 3, 2024
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Sahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Carmelo Romano, Santiago Mendez Huergo, Jonathan Weyne, Tave Van Zyl
  • Treatment Of B27-Negative Uveitis With Inositol Polyphosphate Multikinase (IPMK) Therapeutic Agents Or Indoleamine 2,3-dioxygenase 2 (IDO2) Agonists
    Publication number: 20240238384
    Abstract: Methods of treating B27-negative subjects having uveitis with an Inositol Polyphosphate Multikinase (IPMK) therapeutic agent and/or an Indoleamine 2,3-dioxygenase 2 (IDO2) agonist, and methods of identifying subjects having an increased risk of developing uveitis are described herein.
    Type: Application
    Filed: January 16, 2024
    Publication date: July 18, 2024
    Inventors: Sahar Gelfman, Arden Moscati, Aris Baras, Eli A. Stahl, Giovanni Coppola, Ann Ligocki, Carmelo Romano, Santiago Mendez Huergo, Jonathan Weyne, Tave Van Zyl, Rujin Wang, Charles Miller
  • Treatment Of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Inhibitors
    Publication number: 20230250434
    Abstract: The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.
    Type: Application
    Filed: October 13, 2022
    Publication date: August 10, 2023
    Inventors: Sahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Carmelo Romano, Santiago Mendez Huergo, Jonathan Weyne, Tave Van Zyl
  • Modulation Of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2)-Mediated Immune Response
    Publication number: 20230059929
    Abstract: The present disclosure provides methods of treating subjects having an immune disorder by administering a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor to the subject, and optionally an Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) agonist or inhibitor and/or an HLA-Aw19 inhibitor, and also provides methods of identifying subjects having an increased risk for developing an MHC-I-opathy.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 23, 2023
    Inventors: Sahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Jack A. Kosmicki, Manuel Allen Revez Ferreira, Carmelo Romano
  • Materials And Methods Of Treating MHC-1-Opathy Risk Haplotypes
    Publication number: 20220323581
    Abstract: The present disclosure provides methods of treating subjects having an immune disorder by administering to the subject a therapeutically effective amount of an Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) inhibitor in combination with an HLA-A29 or HLA-B27 inhibitory nucleic acid molecule.
    Type: Application
    Filed: April 6, 2022
    Publication date: October 13, 2022
    Inventors: Sahar Gelfman, Ann Ligocki, Giovanni Coppola, Aris Baras, Arden Moscati, Eli A. Stahl, Jack A. Kosmicki, Manuel Allen Revez Ferreira, Carmelo Romano